Skip to main content
. 2018 Jun 21;9:664. doi: 10.3389/fphar.2018.00664

FIGURE 5.

FIGURE 5

Trimebutine inhibits activation of ERK and AKT signaling pathways in glioma cells. (A) p-AKT and p-ERK protein levels were detected by western blot in SHG44 cells after treatment with various concentrations of trimebutine for 48 and 72 h. (B) p-AKT and p-ERK protein levels were detected by western blot in U251 cells after treatment with various concentrations of trimebutine for 48 and 72 h. (C) p-AKT and p-ERK protein levels were detected by western blot in U87 cells after treatment with various concentrations of trimebutine for 48 and 72 h.